Results 21 to 30 of about 155,038 (165)

Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model

Haematologica, 2020
Although highly effective, BCR-ABL1 tyrosine kinase inhibitors do not target chronic myeloid leukemia (CML) stem cells. Most patients relapse upon tyrosine kinase inhibitor therapy cessation.
Bing Z. Carter, Po Yee Mak, Hong Mu, Xiangmeng Wang, Wenjing Tao, Duncan H. Mak, Elisha J. Dettman, Michael Cardone, Oleg Zernovak, Takahiko Seki, Michael Andreeff   +10 more
doaj   +1 more source

Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models

Frontiers in Immunology, 2022
Immunotherapy with T-cells expressing bispecific T-cell engagers (ENG T-cells) is a promising approach to improve the outcomes for patients with recurrent/refractory acute myeloid leukemia (AML).
Hong Mu-Mosley, Lauren Ostermann, Muharrem Muftuoglu, Abishek Vaidya, Challice L. Bonifant, Mireya Paulina Velasquez, Stephen Gottschalk, Michael Andreeff   +7 more
doaj   +1 more source

Superoxide Dismutase and Vitamin E Levels in Serum as Indicators in Patients with Acute and Chronic Leukemia [PDF]

Journal of Applied Sciences and Nanotechnology, 2022
Oxidative stress has been linked to the development of a variety of malignancies, including leukemia. Furthermore, the incidence of leukemia increases with age due to an increase in the number of free radicals reacting with age and a lower ability of the
Reem Al-Qaisi, Abdulnasser Al-Gebori, Mohammed Alosami   +2 more
doaj   +1 more source

Influencing factors of cancer-related fatigue in acute leukemia patients: A cross-sectional study

Heliyon, 2023
To investigate influencing factors of cancer-related fatigue (CRF) in adult patients with acute leukemia (AL).A total of 288 adult patients diagnosed with acute leukemia in West China Hospital were included in this study. A cross-sectional survey, including the Clinical Information Questionnaire, the Functional Assessment of Chronic Illness Therapy ...
Yingli Wang, Xinwen Du, Yuping Gong, Yan Jiang, Yuhuan Zheng   +4 more
openaire   +3 more sources

Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial

Haematologica, 2018
Targeted therapies against FLT3-mutated acute myeloid leukemias have shown limited clinical efficacy primarily because of the acquisition of secondary mutations in FLT3 and persistent activation of downstream pro-survival pathways such as MEK/ERK, PI3K ...
Weiguo Zhang, Charlie Ly, Jo Ishizawa, Hong Mu, Vivian Ruvolo, Sharon Shacham, Naval Daver, Michael Andreeff   +7 more
doaj   +1 more source

The Regulation of Neutrophil Migration in Patients with Sepsis: The Complexity of the Molecular Mechanisms and Their Modulation in Sepsis and the Heterogeneity of Sepsis Patients

Cells, 2023
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. Common causes include gram-negative and gram-positive bacteria as well as fungi.
Øystein Bruserud, Knut Anders Mosevoll, Øyvind Bruserud, Håkon Reikvam, Øystein Wendelbo   +4 more
doaj   +1 more source

The Current Understanding of and Treatment Paradigm for Newly-Diagnosed TP53-Mutated Acute Myeloid Leukemia

Hemato, 2021
About 10% of newly diagnosed and 20–30% of therapy-related acute myeloid leukemia (AML) harbors a TP53 mutation (mTP53-AML). Unfortunately, this biological subset predicts one of the worst prognoses among patients with AML, specifically a median overall ...
Rory M. Shallis, Maximilian Stahl, Jan Philipp Bewersdorf, Amer M. Zeidan   +3 more
doaj   +1 more source

Extending the duration of response in chronic myelogenous leukemia: targeted therapy with sequential tyrosine kinase inhibitors

Oncology Reviews, 2011
Tyrosine kinase inhibitors (TKIs) are the mainstay for treatment of chronic myelogenous leukemia (CML). Imatinib was the first TKI approved for use in CML, but resistance to this therapy has emerged as a significant issue, and second-line options are ...
Michael G. Martin, John F. DiPersio, Geoffrey L. Uy   +2 more
doaj   +1 more source

Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang

Cancer Biology & Medicine, 2016
Acute myeloid leukemia (AML) is characterized by the accumulation of circulating immature blasts that exhibit uncontrolled growth, lack the ability to undergo normal differentiation, and have decreased sensitivity to apoptosis.
Hong-Sheng Zhou, Bing Z. Carter, Michael Andreeff   +2 more
doaj   +1 more source

Targeting Bruton’s Tyrosine Kinase in CLL

Frontiers in Immunology, 2021
Targeting the B-cell receptor signaling pathway through BTK inhibition proved to be effective for the treatment of chronic lymphocytic leukemia (CLL) and other B-cell lymphomas.
Inhye E. Ahn, Jennifer R. Brown
doaj   +1 more source